Lobe Sciences Ltd (OTCMKTS:GTSIF) Stock Soars 45% After Preclinical Research Studies Data

The publication of interim data with regards to any product or treatment can often lead to a big move in a biotech company’s stock price and that is what happened with the Lobe Sciences Ltd (OTCMKTS:GTSIF) stock on Tuesday.

Yesterday the company was in sharp focus after it announced the interim data from the preclinical studies that had been conducted for the treatment of PTSD (post traumatic stress disorder) and mild traumatic brain injuries in rodent models with psilocybin combined with NAC or N-Acetylcysteine. The news came as a big boost for the Lobe Sciences stock, which ended the day with gains of as much as 45%.

Considering the sheer magnitude of the gains clocked by the Lobe Sciences stock, it is likely that the stock is going to be in focus among investors today as well. It is a pivotal study for the company and is being conducted in collaboration with physicians as well as scientists from the University Of Miami Miller School Of Medicine.

The study is being led by Michael E Hoffer, who is a professor of neurological surgery and otolaryngology. At this point in time, it might be a good move for investors to add the stock to their watch lists.